Yixintang Pharmaceutical Group Future Growth

Future criteria checks 3/6

Yixintang Pharmaceutical Group is forecast to grow earnings and revenue by 38.2% and 13.2% per annum respectively. EPS is expected to grow by 42.9% per annum. Return on equity is forecast to be 11.5% in 3 years.

Key information

38.2%

Earnings growth rate

42.9%

EPS growth rate

Consumer Retailing earnings growth	48.3%
Revenue growth rate	13.2%
Future return on equity	11.5%
Analyst coverage	Good
Last updated	19 Dec 2024

Recent future growth updates

Recent updates

Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Dec 12

Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Nov 22

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Nov 06

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06

Earnings and Revenue Growth Forecasts

SZSE:002727 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	26,321	1,227	1,307	N/A	1
12/31/2026	24,688	926	1,180	1,839	11
12/31/2025	21,374	780	1,119	2,003	12
12/31/2024	18,396	598	898	1,123	8
9/30/2024	18,157	156	1,762	2,015	N/A
6/30/2024	18,010	327	2,086	2,355	N/A
3/31/2024	18,044	552	1,985	2,269	N/A
12/31/2023	17,380	549	1,862	2,115	N/A
9/30/2023	18,219	1,019	1,971	2,361	N/A
6/30/2023	18,142	1,096	2,234	2,553	N/A
3/31/2023	17,872	1,070	2,402	2,733	N/A
1/1/2023	17,432	1,010	2,148	2,497	N/A
9/30/2022	16,115	835	2,125	2,509	N/A
6/30/2022	15,851	816	1,537	1,947	N/A
3/31/2022	15,154	840	1,295	1,668	N/A
1/1/2022	14,587	922	1,400	1,792	N/A
9/30/2021	13,916	950	815	1,120	N/A
6/30/2021	13,329	897	610	928	N/A
3/31/2021	12,998	846	690	988	N/A
12/31/2020	12,656	790	753	1,033	N/A
9/30/2020	12,056	724	827	1,023	N/A
6/30/2020	11,448	683	1,077	1,257	N/A
3/31/2020	10,978	633	984	1,185	N/A
12/31/2019	10,479	604	776	983	N/A
9/30/2019	10,219	587	838	1,017	N/A
6/30/2019	9,945	566	719	892	N/A
3/31/2019	9,585	565	828	988	N/A
1/1/2019	9,176	521	480	636	N/A
9/30/2018	8,768	525	481	619	N/A
6/30/2018	8,391	499	N/A	579	N/A
3/31/2018	8,116	457	N/A	330	N/A
12/31/2017	7,751	423	N/A	391	N/A
9/30/2017	7,316	386	N/A	166	N/A
6/30/2017	6,949	373	N/A	44	N/A
3/31/2017	6,584	345	N/A	134	N/A
12/31/2016	6,249	353	N/A	193	N/A
9/30/2016	5,971	379	N/A	124	N/A
6/30/2016	5,774	369	N/A	220	N/A
3/31/2016	5,600	361	N/A	163	N/A
12/31/2015	5,321	346	N/A	187	N/A
9/30/2015	5,080	323	N/A	234	N/A
6/30/2015	4,854	314	N/A	58	N/A
3/31/2015	4,589	310	N/A	34	N/A
12/31/2014	4,428	297	N/A	176	N/A
9/30/2014	4,236	292	N/A	211	N/A
6/30/2014	3,995	279	N/A	228	N/A
3/31/2014	3,792	253	N/A	284	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002727's forecast earnings growth (38.2% per year) is above the savings rate (2.8%).

Earnings vs Market: 002727's earnings (38.2% per year) are forecast to grow faster than the CN market (25.4% per year).

High Growth Earnings: 002727's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002727's revenue (13.2% per year) is forecast to grow slower than the CN market (13.7% per year).

High Growth Revenue: 002727's revenue (13.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002727's Return on Equity is forecast to be low in 3 years time (11.5%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 09:43
End of Day Share Price	2024/12/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yixintang Pharmaceutical Group Co., Ltd. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Haigang Chen	China International Capital Corporation Limited
Feifei Xu	China Merchants Securities Co. Ltd.
Bing Zhao	China Renaissance Securities

Yixintang Pharmaceutical Group Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 9.0% to CN¥15.14

Consensus EPS estimates fall by 26%

Consensus EPS estimates fall by 32%

Price target decreased by 10% to CN¥20.81

Consensus revenue estimates decrease by 11%

Price target decreased by 8.1% to CN¥35.37

Recent updates

Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Price target decreased by 9.0% to CN¥15.14

Consensus EPS estimates fall by 26%

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS misses analyst expectations

Yixintang Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 18%

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Consensus EPS estimates fall by 32%

Price target decreased by 10% to CN¥20.81

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024.

Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024.

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Now 20% overvalued

Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Dividend of CN¥0.40 announced

Yixintang Pharmaceutical Group Co., Ltd. Announces Dividend Implementation for 2023, Payable on 30 May 2024

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.70 in FY 2022)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Now 21% undervalued after recent price drop

Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Consensus revenue estimates decrease by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 2Q 2022)

Price target decreased by 8.1% to CN¥35.37

Yixintang Pharmaceutical Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023

Yixintang Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings released: EPS: CN¥1.70 (vs CN¥1.56 in FY 2021)

Price target increased to CN¥38.51

Investor sentiment improved over the past week

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to CN¥33.64

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥40.40

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥46.85

High number of new directors

Yixintang Pharmaceutical Group Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2021, Payable on April 29, 2022

Yixintang Pharmaceutical Group Co., Ltd. Approves Profit Distribution

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 20, 2022

Price target decreased to CN¥46.85

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.37 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.36 in 1Q 2020)

Price target increased to CN¥50.86

Investor sentiment improved over the past week

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)